Mesa files Agena financials post-acquisition; revises segment reporting structure

MESA LABORATORIES INC /CO/

Agena's revenue for nine months ended Sep 30, 2021: $58.4M, up 45% YoY; net income of $12.8M vs loss of $0.38M.
Mesa recast FY2021 segment data into four segments: Sterilization/Disinfection, Clinical Genomics (Agena), Biopharma Development, Calibration Solutions.
Pro forma combined statement for nine months ended Dec 31, 2021 filed; acquisition closed Oct 20, 2021.
Agena's cash and equivalents fell to $3.7M from $16.1M at Dec 31, 2020; debt repaid $22.5M during period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.